Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Statins, commonly used to treat hypercholesterolemia, have been shown to trigger tumor-specific apoptosis in certain cancers, including multiple myeloma (MM), a plasma cell malignancy with poor prognosis. In this article, we show that of a panel of 17 genetically distinct MM cell lines, half were sensitive to statin-induced apoptosis and, despite pharmacodynamic evidence of drug uptake and activity, the remainder were insensitive. Sensitive cells were rescued from lovastatin-induced apoptosis by mevalonate, geranylgeranyl PPi, and partially by farnesyl PPi, highlighting the importance of isoprenylation. Expression profiling revealed that Rho GTPase mRNAs were differentially expressed upon lovastatin exposure in sensitive cells, yet ectopic expression of constitutively active Rho or Ras proteins was insufficient to alter sensitivity to lovastatin-induced apoptosis. This suggests that sensitivity involves more than one isoprenylated protein and that statins trigger apoptosis by blocking many signaling cascades, directly or indirectly deregulated by the oncogenic lesions of the tumor cell. Indeed, clustering on the basis of genetic abnormalities was shown to be significantly associated with sensitivity (P = 0.003). These results suggest that statins may be a useful molecular targeted therapy in the treatment of a subset of MM. [Mol Cancer Ther 2007;6(6):1886–97]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M. (1998) · Blood · doi:10.1182/blood.v91.12.4457.412k48_4457_4463 · Cited by 400
Self-citation
Cited by
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699
Self-citationDysregulation of the mevalonate pathway promotes transformation
Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910258107 · Cited by 417
Self-citationStatins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
“In acute myeloid leukemia and multiple myeloma cells, statin-induced apoptosis can be phenocopied by prenylation inhibitors, which suggests that these cancers rely onGGPP synthesis, at least in part, for protein prenylation (22, 23, 28).”
BackgroundSelf-citationWang, X., Li, C., Ju, S., Wang, Y., Wang, H., & Zhong, R. (2011) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.591004 · Cited by 103
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82
Metadata
- Authors
- Wong, W. W.-L., Clendening, J. W., Martirosyan, A., Boutros, P. C., Bros, C., Khosravi, F., Jurisica, I., Stewart, A. K., Bergsagel, P. L., & Penn, L. Z.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2007-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 1886-1897
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2095681827
- Cited by
- 79
- References
- 1
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0745
- The paper
- Wong, W. W.-L., Clendening, J. W., Martirosyan, A., Boutros, P. C., Bros, C., Khosravi, F., Jurisica, I., Stewart, A. K., Bergsagel, P. L., & Penn, L. Z. (2007). Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0745
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.